Advertisement

Efficacy of novel selective NLRP3 inhibitors in human and murine retinal pigment epithelial cells

  • Luping Wang
  • Sarah Schmidt
  • Petra P. Larsen
  • Johanna H. Meyer
  • William R. Roush
  • Eicke Latz
  • Frank G. Holz
  • Tim U. KrohneEmail author
Original Article

Abstract

NLRP3 inflammasome activation in the retinal pigment epithelium (RPE) is observed in atrophic age-related macular degeneration (AMD), and pharmacological NLRP3 inhibition may provide a therapeutic strategy to halt disease progression. We tested selective NLRP3 inhibitors (IFM-514, IFM-632, and CRID3) for their efficacy in human and murine RPE cells. Inflammasome activation was induced in primary human RPE cells and ARPE-19 cells following priming with IL-1α by different stimuli, including lysosomal membrane permeabilization by leucyl-leucine methyl ester (Leu-Leu-OMe), oxidative damage induced by hydrogen peroxide, lipofuscin-mediated photooxidative damage induced by incubation with 4-hydroxynonenal-modified photoreceptor outer segments and subsequent blue light irradiation, and P2X7 receptor activation by benzoylbenzoyl-ATP. Independent of the applied activation mechanism, treatment with the NLRP3 inhibitors IFM-632, IFM-514, and CRID3 resulted in a significant suppression of inflammasome activation as assessed by IL-1β and LDH release. Likewise, inflammasome activation in blue light-irradiated Abca4−/− mouse and Leu-Leu-OMe-treated wild-type mouse RPE/choroid/sclera eye cups was significantly reduced by treatment with the NLRP3 inhibitors. These results indicate that the investigated selective NLRP3 inhibitors are effective in human and murine RPE cells, thus representing promising agents for the future evaluation of inflammasome inhibition as a therapeutic strategy in atrophic AMD.

Key messages

• NLRP3 inhibitors suppress inflammasome activation in human RPE cells independent of trigger.

• Light-induced inflammasome activation in Abca4−/− mouse eye cups is reduced by NLRP3 inhibitors.

• Novel selective NLRP3 inhibitors are effective in human and murine RPE cells.

• Promising compounds for pharmaceutical intervention in atrophic AMD.

Keywords

Age-related macular degeneration Interleukin-1 Lysosomal membrane permeabilization Oxidative damage P2X7 receptor 

Notes

Acknowledgements

NLRP3 inhibitors IFM-632 and IFM-514 were kindly provided by IFM Therapeutics (Boston, Massachusetts, USA). Abca4−/− mice were a kind gift from Alun Barnard (University of Oxford, Oxford, UK).

Funding information

This work was supported by the China Scholarship Council (CSC; to L.W.), Ernst and Berta Grimmke Foundation (to P.P.L. and T.U.K.), German Research Foundation (DFG; grant KR 2863/7-2 to T.U.K., collaborative research centers SFB/TRR57 and SFB/TRR83), Volker Homann Foundation (to T.U.K.), Dr. Eberhard und Hilde Rüdiger Foundation (to T.U.K.), and the European Research Council (ERC) grant InflammAct (to E.L.).

Compliance with ethical standards

Conflict of interest

L. Wang, S. Schmidt, P. P. Larsen declare that they have no conflict of interest. J. H. Meyer declares support from Heidelberg Engineering. W. R. Roush is a shareholder and employee of IFM Therapeutics. E. Latz is a co-founder and consultant of IFM Therapeutics. F. G. Holz declares support from Acucela, Allergan, Bayer, Centervue, NightstarX, Novartis, Genentech/Roche, Heidelberg Engineering, Optos, and Carl Zeiss Meditec. T. U. Krohne declares support from Alimera Sciences, Bayer, Heidelberg Engineering, and Novartis.

References

  1. 1.
    European Society of Retina Specialists (EURETINA) (2017) Retinal diseases in Europe: prevalence, incidence and healthcare needs. Available online at http://www.euretina.org/downloads/EURETINA_Retinal_Diseases.pdf. Accessed 31 Aug 2018
  2. 2.
    Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY (2012) Age-related macular degeneration. Lancet 379:1728–1738CrossRefGoogle Scholar
  3. 3.
    Tarallo V, Hirano Y, Gelfand BD, Dridi S, Kerur N, Kim Y, Cho WG, Kaneko H, Fowler BJ, Bogdanovich S et al (2012) DICER1 loss and Alu RNA induce age-related macular degeneration via the NLRP3 inflammasome and MyD88. Cell 149:847–859Google Scholar
  4. 4.
    Doyle SL, Campbell M, Ozaki E, Salomon RG, Mori A, Kenna PF, Farrar GJ, Kiang AS, Humphries MM, Lavelle EC et al (2012) NLRP3 has a protective role in age-related macular degeneration through the induction of IL-18 by drusen components. Nat Med 18:791–798Google Scholar
  5. 5.
    Tseng WA, Thein T, Kinnunen K, Lashkari K, Gregory MS, D’Amore PA, Ksander BR (2013) NLRP3 inflammasome activation in retinal pigment epithelial cells by lysosomal destabilization: implications for age-related macular degeneration. Invest Ophthalmol Vis Sci 54:110–120Google Scholar
  6. 6.
    Cao S, Wang JC, Gao J, Wong M, To E, White VA, Cui JZ, Matsubara JA (2016) CFH Y402H polymorphism and the complement activation product C5a: effects on NF-κB activation and inflammasome gene regulation. Br J Ophthalmol 100:713–718Google Scholar
  7. 7.
    Ijima R, Kaneko H, Ye F, Nagasaka Y, Takayama K, Kataoka K, Kachi S, Iwase T, Terasaki H (2014) Interleukin-18 induces retinal pigment epithelium degeneration in mice. Invest Ophthalmol Vis Sci 55:6673–6678Google Scholar
  8. 8.
    Budiene B, Liutkeviciene R, Gustiene O, Ugenskiene R, Laukaitiene D, Savukaityte A, Vilkeviciute A, Steponaviciute R, Rocyte A, Zaliuniene D (2018) The association of matrix metalloproteinases polymorphisms and interleukins in advanced age-related macular degeneration. Ophthalmic Genet 39:463–472Google Scholar
  9. 9.
    Zhao M, Bai Y, Xie W, Shi X, Li F, Yang F, Sun Y, Huang L, Li X (2015) Interleukin-1β level is increased in vitreous of patients with neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV). PLoS One 10:1–10Google Scholar
  10. 10.
    Gao J, Cui JZ, To E, Cao S, Matsubara JA (2018) Evidence for the activation of pyroptotic and apoptotic pathways in RPE cells associated with NLRP3 inflammasome in the rodent eye. J Neuroinflammation 15:15Google Scholar
  11. 11.
    Brandstetter C, Patt J, Holz FG, Krohne TU (2016) Inflammasome priming increases retinal pigment epithelial cell susceptibility to lipofuscin phototoxicity by changing the cell death mechanism from apoptosis to pyroptosis. J Photochem Photobiol B 161:177–183CrossRefGoogle Scholar
  12. 12.
    Akhtar-Schäfer I, Wang L, Krohne TU, Xu H, Langmann T (2018) Modulation of three key innate immune pathways for the most common retinal degenerative diseases. EMBO Mol Med 10:e8259CrossRefPubMedCentralGoogle Scholar
  13. 13.
    Heneka MT, McManus RM, Latz E (2018) Inflammasome signalling in brain function and neurodegenerative disease. Nat Rev Neurosci 19:610–621CrossRefGoogle Scholar
  14. 14.
    Latz E, Xiao TS, Stutz A (2013) Activation and regulation of the inflammasomes. Nat Rev Immunol 13:397–411CrossRefGoogle Scholar
  15. 15.
    Karmakar M, Katsnelson M, Malak HA, Greene NG, Howell SJ, Hise AG, Camilli A, Kadioglu A, Dubyak GR, Pearlman E (2018) Neutrophil IL-1 β processing induced by pneumolysin is mediated by the NLRP3/ASC inflammasome and caspase-1 activation and is dependent on K+ efflux. J Immunol 194:1763–1775Google Scholar
  16. 16.
    Liu RT, Wang A, To E, Gao J, Cao S, Cui JZ, Matsubara JA (2015) Vinpocetine inhibits amyloid-beta induced activation of NF-κB, NLRP3 inflammasome and cytokine production in retinal pigment epithelial cells. Exp Eye Res 127:49–58Google Scholar
  17. 17.
    Brandstetter C, Mohr LKM, Latz E, Holz FG, Krohne TU (2015) Light induces NLRP3 inflammasome activation in retinal pigment epithelial cells via lipofuscin-mediated photooxidative damage. J Mol Med 93:905–916CrossRefPubMedCentralGoogle Scholar
  18. 18.
    Yang D, Elner SG, Clark AJ, Hughes BA, Petty HR, Elner VM (2011) Activation of P2X receptors induces apoptosis in human retinal pigment epithelium. Invest Opthalmol Vis Sci 52:1522–1530CrossRefGoogle Scholar
  19. 19.
    IFM Therapeutics (2017) Compounds and compositions for treating conditions associated with NLRP activity. World Intellectual Property Organization (WIPO), Geneva, Switzerland; publication number WO/2017/184624. Available online at https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2017184624. Accessed 31 Aug 2018
  20. 20.
    Coll RC, Robertson AAB, Chae JJ, Higgins SC, Muñoz-Planillo R, Inserra MC, Vetter I, Dungan LS, Monks BG, Stutz A et al (2015) A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med 21:248–255Google Scholar
  21. 21.
    Primiano MJ, Lefker BA, Bowman MR, Bree AG, Hubeau C, Bonin PD, Mangan M, Dower K, Monks BG, Cushing L et al (2018) Efficacy and pharmacology of the NLRP3 inflammasome inhibitor CP-456,773 (CRID3) in murine models of dermal and pulmonary. Inflammation 773:2421–2433Google Scholar
  22. 22.
    Krohne TU, Stratmann NK, Kopitz J, Holz FG (2010) Effects of lipid peroxidation products on lipofuscinogenesis and autophagy in human retinal pigment epithelial cells. Exp Eye Res 90:465–471Google Scholar
  23. 23.
    Krohne TU, Kaemmerer E, Holz FG (2010) Lipid peroxidation products reduce lysosomal protease activities in human retinal pigment epithelial cells via two different mechanisms of action. Exp Eye Res 90:261–266Google Scholar
  24. 24.
    Charbel Issa P, Barnard AR, Singh MS, Carter E, Jiang Z, Radu RA, Schraermeyer U, MacLaren RE (2013) Fundus autofluorescence in the Abca4 −/− mouse model of Stargardt disease—correlation with accumulation of A2E, retinal function, and histology. Invest Ophthalmol Vis Sci 54:5602–5612Google Scholar
  25. 25.
    Weng J, Mata NL, Azarian SM, Tzekov RT, Birch DG, Travis GH (1999) Insights into the function of rim protein in photoreceptors and etiology of Stargardt’s disease from the phenotype in abcr knockout mice. Cell 98:13–23CrossRefGoogle Scholar
  26. 26.
    Kanneganti TD, Ozoren N, Body-Malapel M, Amer A, Park JH, Franchi L, Whitfield J, Barchet W, Colonna M, Vandenabeele P et al (2006) Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature 440:233–236Google Scholar
  27. 27.
    Mohr LK, Hoffmann AV, Brandstetter C, Holz FG, Krohne TU (2015) Effects of inflammasome activation on secretion of inflammatory cytokines and vascular endothelial growth factor by retinal pigment epithelial cells. Investig Opthalmol Vis Sci 56:6404Google Scholar
  28. 28.
    Dutot M, Liang H, Pauloin T, Brignole-Baudouin F, Baudouin C, Warnet JM, Rat P (2008) Effects of toxic cellular stresses and divalent cations on the human P2X7 cell death receptor. Mol Vis 14:889–897 PubMedCentralGoogle Scholar
  29. 29.
    Katsnelson MA, Rucker LG, Russo HM, Dubyak GR (2015) K+ efflux agonists induce NLRP3 inflammasome activation independently of Ca2+ signaling. J Immunol 194:3937–3952CrossRefPubMedCentralGoogle Scholar
  30. 30.
    Guha S, Baltazar GC, Coffey EE, Tu LA, Lim JC, Beckel JM, Patel S, Eysteinsson T, Lu W, O’Brien-Jenkins A et al (2013) Lysosomal alkalinization, lipid oxidation, and reduced phagosome clearance triggered by activation of the P2X7 receptor. FASEB J 27:4500–4509Google Scholar
  31. 31.
    Nalbandian A, Khan AA, Srivastava R, Llewellyn KJ, Tan B, Shukr N, Fazli Y, Kimonis VE, BenMohamed L (2017) Activation of the NLRP3 inflammasome is associated with Valosin-containing protein myopathy. Inflammation 40:21–41CrossRefPubMedCentralGoogle Scholar
  32. 32.
    Ludwig-portugall I, Bartok E, Dhana E, Evers BD, Primiano MJ, Hall JP, Franklin BS, Knolle PA, Hornung V, Hartmann G et al (2016) An NLRP3-specific inflammasome inhibitor attenuates crystal-induced kidney fibrosis in mice. Kidney Int 90:525–539Google Scholar
  33. 33.
    Dempsey C, Rubio Araiz A, Bryson KJ, Finucane O, Larkin C, Mills EL, Robertson AAB, Cooper MA, O’Neill LAJ, Lynch MA (2017) Inhibiting the NLRP3 inflammasome with MCC950 promotes non-phlogistic clearance of amyloid-β and cognitive function in APP/PS1 mice. Brain Behav Immun 61:306–316CrossRefGoogle Scholar
  34. 34.
    Zhou R, Yazdi AS, Menu P (2011) A role for mitochondria in NLRP3 inflammasome activation. Nature 469:221–225Google Scholar
  35. 35.
    Giuliani AL, Sarti AC, Falzoni S, Di Virgilio F (2017) The P2X7 receptor-interleukin-1 liaison. Front Pharmacol 8:1–10CrossRefGoogle Scholar
  36. 36.
    Arulkumaran N, Unwin RJ, Tam FWK (2011) A potential therapeutic role for P2X7 receptor (P2X7R) antagonists in the treatment of inflammatory diseases. Expert Opin Investig Drugs 20:897–915Google Scholar
  37. 37.
    Di Virgilio F, Ben DD, Sarti AC, Giuliani AL, Falzoni S (2017) The P2X7 receptor in infection and inflammation. Immunity 47:15–31Google Scholar
  38. 38.
    Kerur N, Hirano Y, Tarallo V, Fowler BJ, Bastos-Carvalho A, Yasuma T, Yasuma R, Kim Y, Hinton DR, Kirschning CJ et al (2013) TLR-independent and P2X7-dependent signaling mediate Alu RNA-induced NLRP3 inflammasome activation in geographic atrophy. Invest Ophthalmol Vis Sci 54:3–9Google Scholar
  39. 39.
    Notomi S, Hisatomi T, Murakami Y, Terasaki H, Sonoda S, Asato R, Takeda A, Ikeda Y, Enaida H, Sakamoto T et al (2013) Dynamic increase in extracellular ATP accelerates photoreceptor cell apoptosis via ligation of P2RX7 in subretinal hemorrhage. PLoS One 8:e53338Google Scholar
  40. 40.
    Notomi S, Hisatomi T, Kanemaru T, Takeda A, Ikeda Y, Enaida H, Kroemer G, Ishibashi T (2011) Critical involvement of extracellular ATP acting on P2RX7 purinergic receptors in photoreceptor cell death. Am J Pathol 179:2798–2809CrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of OphthalmologyUniversity of BonnBonnGermany
  2. 2.IFM TherapeuticsBostonUSA
  3. 3.Institute of Innate ImmunityUniversity of BonnBonnGermany
  4. 4.German Center for Neurodegenerative Diseases (DZNE)BonnGermany
  5. 5.Department of Infectious Diseases and ImmunologyUniversity of Massachusetts Medical SchoolWorcesterUSA
  6. 6.Centre of Molecular Inflammation Research, Department of Cancer Research and Molecular MedicineNorwegian University of Science and Technology (NTNU)TrondheimNorway

Personalised recommendations